Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2013

Cytori Taps Medistem Technology for Autoimmune Disease Drug Development

  • San Diego, CA-based Cytori Therapeutics is using Medistem’s patented “Stem Cell Mediated Treg Activation” technology to develop autoimmune disease treatments.

    Under the terms of the agreement, Cytori gains a license and exclusive rights to use Medistem technology outlined in U.S. Patent No. 8,241,621. Cytori will use Medistem technology in efforts related to its Adipose-Derived Regenerative Cell-based platform for the treatment of autoimmune diseases. Financial terms were not disclosed.

    “We are delighted to have formalized a licensing agreement with an adult stem cell leader like Cytori and look forward to working with them in the future,” Medistem CEO Alan J. Lewis, Ph.D., said in a statement.

    Added Cytori’s Marc H. Hedrick, president: “We are pleased to have licensed this patent from Medistem because it strengthens our patent portfolio in the area of immune disease.”



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »